Executive Summary

• The Trump Administration announced a new Section 232 tariff regime targeting patented pharmaceuticals and associated pharmaceutical ingredients, tying the policy to both manufacturing onshoring and most-favored-nation pricing metrics.
• The proclamation establishes a default 100 percent tariff on identified patented drugs and related inputs, a 20 percent tariff rate for companies with Department of Commerce-approved plans to onshore production, and lower rates for other nations with already signed trade deals.
• While tariffs may be able to coerce behavior, they are a poor instrument to address affordability concerns and onshore pharmaceutical production; given the administration’s regularly shifting trade policies, they are especially ill-suited to an industry as costly, complex, and internationally integrated as pharmaceuticals.

Introduction

On April 2, 2026, the Trump Administration announced a new Section 232 tariff regime targeting patented pharmaceuticals and associated pharmaceutical ingredients, presenting the policy as both a national-security intervention and a means of reducing prescription drug prices. The proclamation establishes a default 100 percent tariff on identified patented drugs and related inputs. For certain companies, the tariffs take effect on July 31, 2026; for others, they begin on September 29, 2026. The White House has described this bifurcation as a staggered implementation window of 120 days for some larger firms and 180 days for smaller ones. There is variability beyond the default rate for companies that adhere to pharmaceutical pricing and manufacturing policies preferred by the administration.

The particulars of the announcement make clear the administration does not merely seek to reorient supply chains or encourage domestic production. It is attempting to use tariff policy as a vehicle for industrial policy, pricing policy, and geopolitical leverage all at once. These new tariffs are simultaneously intended to reduce domestic drug prices, compel companies to join most-favored-nation (MFN) pricing accords and onshore pharmaceutical manufacturing facilities, and lead trading partners to make concessions to the administration.

There is a fundamental conceptual problem: Tariffs are a poor instrument for addressing concerns about drug pricing, and they are especially ill-suited to an industry as costly, complex, and internationally integrated as pharmaceuticals.

A Circular Policy Problem

The proclamation articulates a highly conditional framework, structured around country-specific treatment, firm-specific concessions, and future policy negotiations. Companies that have executed MFN agreements with the U.S. government, which include both onshoring and pricing commitments, will have no tariffs associated with this action until 2029. Companies with Department of Commerce-approved plans to onshore production but without MFN-style pricing concessions may qualify for a 20 percent tariff rate, though that reduced rate is scheduled to rise to 100 percent on April 2, 2030. Products from the European Union, Japan, South Korea, Switzerland, and Liechtenstein are generally subject to a 15 percent rate, while products from the United Kingdom face a 10 percent rate, with the possibility of falling to zero if a future bilateral pricing arrangement so provides.

The proclamation also provides an exemption for several specialized product categories, including drugs for which the approved indications are entirely orphan-designated, nuclear medicines, plasma-derived therapies, fertility treatments, cell and gene therapies, antibody-drug conjugates, certain medical countermeasures, and some animal-health products, subject to the administration’s criteria. It also excludes generic drugs, biosimilars, and their associated ingredients for the time being, while directing Commerce to revisit whether a separate generic tariff action may be warranted within a year.

The administration’s approach creates a kind of policy catch-22 because the three levers it is pulling operate on three different actors, none of which directly controls the others. Tariffs are imposed on manufacturers and importers, forcing companies to absorb higher costs or alter supply chains. MFN pricing, however, is fundamentally a function of foreign government reimbursement systems, formularies, and price-setting institutions – matters well beyond the unilateral control of the firms being pressured. Onshoring, meanwhile, depends not simply on corporate will, but on whether U.S. domestic policy makes large-scale pharmaceutical manufacturing commercially and operationally viable through permitting, regulatory predictability, tax treatment, infrastructure, and labor conditions.

The result is a framework in which companies are punished for pricing decisions made abroad and for production choices shaped by domestic policy constraints at home. Rather than aligning incentives, the policy disperses responsibility among actors with different authorities, making it far more difficult for any single lever to achieve the outcome it is ostensibly designed to produce.

Tying One Bad Policy to Another

Centering the tariff regime on MFN pricing as the main pathway toward relief reveals the misguided nature of this policy. Companies that qualify for the onshoring pathway and also enter into MFN pricing agreements with the Department of Health and Human Services may receive an exemption through January 20, 2029. The administration is therefore not simply attempting to encourage domestic pharmaceutical production, but conditioning tariff relief on compliance with an externally anchored drug-pricing framework using Section 232 as leverage to extract both manufacturing commitments and pricing concessions from firms.

The problem begins with the mismatch between the administration’s diagnosis and its chosen instrument. If the policy concern is that foreign governments pay less for innovative medicines than the United States, then the source of that disparity lies in foreign reimbursement systems: reference pricing, national formularies, budget constraints, administrative negotiation, and state-driven price suppression. A tariff imposed at the U.S. border does not alter any of those policies. It does not require another country to revise its reimbursement rules. It does not compel foreign health systems to bear a greater share of global biopharmaceutical costs. It merely taxes the importation of a product into the United States. To describe that as a remedy for MFN pricing is to conflate foreign pricing distortion with domestic import taxation.

Given Congress’ frosty reception to codifying MFN, the tariff regime could also be understood as a possible effort to extend MFN-style pricing discipline without legislative action. The proclamation conditions tariff treatment on MFN pricing agreements. Companies are (forcibly) encouraged to treat MFN not as a transient political demand, but as part of a longer-lived commercial environment. That is what makes the linkage so consequential: It looks less like ordinary trade policy than an attempt to give MFN staying power through executive design that Congress has – thankfully – been hesitant to codify directly.

Raising Taxes Does Not Inherently Lower Prices

Whatever political rhetoric may accompany them, tariffs’ economic incidence does not disappear because the product in question is a medicine rather than a machine part or consumer appliance. Research on prior U.S. tariff actions found that the burden of many tariffs fell substantially on domestic purchasers, rather than being wholly absorbed by foreign exporters. More recent pharmaceutical-specific modeling points in the same direction. A Health Affairs Scholar analysis of tariffs on imported active pharmaceutical ingredients used in domestically produced generics estimated that a 100 percent worldwide tariff could raise average finished-drug prices by roughly 30 percent under baseline assumptions, while a blended tariff scenario could still generate meaningful price increases. The precise magnitude may differ across branded and patented products, but the operative logic remains unchanged: When government taxes imported pharmaceutical inputs or finished products, the domestic supply chain becomes more expensive.

That point becomes even more serious when placed in the context of the industry the administration has chosen to tax. Pharmaceuticals are not a low-cost sector with large idle profit margins waiting to absorb a major new trade burden. They are a research-intensive, capital-intensive, compliance-intensive industry characterized by large upfront investment, long development timelines, manufacturing complexity, and extensive regulatory obligations. The Congressional Budget Office has found that pharmaceutical firms devoted an average of roughly 19 percent of net revenues to research and development over the prior two decades. The administration’s proclamation also acknowledges that the United States remains heavily reliant on foreign production: As of 2025, approximately 53 percent of patented pharmaceutical products distributed domestically were produced outside the country, while only 15 percent of patented active pharmaceutical ingredients (APIs) by volume were domestically produced for the U.S. market.

That is the central contradiction at the heart of the policy. The administration purports to be lowering prices by imposing a tax on an industry it simultaneously recognizes as both expensive to sustain and substantially dependent on imported production and inputs. That is not disciplined economic reasoning. It is policy inversion. Instead of addressing the foreign pricing mechanisms said to be the problem, the government has chosen to raise domestic costs in the hope that coercive pressure on manufacturers will somehow yield lower prices for U.S. patients. Such a strategy is neither intellectually defensible nor stable. It compresses firms from both sides: higher supply-side costs through tariffs, and lower revenue expectations through MFN pricing pressure. That may produce compliance in the short term, but it is not effective and durable reform.

A credible pharmaceutical manufacturing policy agenda would emphasize predictable permitting, regulatory modernization, targeted incentives for critical inputs and advanced production, more reliable procurement, and a thoughtful assessment of where strategic domestic capacity is genuinely necessary. A credible drug-pricing agenda would focus on competition, market structure, formulary incentives, benefit design, faster generic and biosimilar uptake, and the other distortions that shape U.S. pharmaceutical spending. And a credible response to foreign underpayment would proceed through trade negotiations and diplomatic channels aimed directly at the reimbursement practices in question. The administration instead has collapsed all three objectives into a single tariff announcement and asks observers to believe that this amalgam constitutes durable, deeply considered policy decisions.

And durable policy, it is not. It reflects impatience with policy discipline itself. Section 232 pharmaceutical tariffs are being marketed as though they can simultaneously re-shore production, discipline foreign governments, and reduce prices at home. But a tariff is not transformed into a precise affordability instrument merely because it is attached to medicines. It remains a tax, and in a sector as intricate and cost-intensive as pharmaceuticals, new taxes tend to reverberate long before they directly impact their intended policy target.

Conclusion

Tariffs may be able to coerce behavior, but they are a poor substitute for coherent drug-pricing reform. If the goal is domestic manufacturing resilience, policymakers should use targeted onshoring incentives, regulatory modernization, and procurement tools. If the goal is to address pricing concerns, policymakers should accelerate biosimilar and generic competition, reduce anti-competitive contracting and rebate distortions, increase net-price transparency where feasible, and make benefit design protect patients from high cost-sharing without importing foreign price controls as a statutory crutch. What the administration should not do is pretend that a tax on imported medicines and inputs is somehow a direct and defensible consumer price-reduction strategy. It is not. It is more likely to raise costs, distort launch decisions, and confuse industrial policy with health policy.